This article reviews Dengue, a common viral disease in humans and is an emerging public health problem in Terai Region of Nepal.
Introduction
Dengue viruses (DENVs), which belong to the genus Flavivirus, family Flaviviridae, comprise four serotype named dengue virus types 1, 2, 3, and 4 (DENV-1, -2, -3, and -4). Infection with any of these serotypes leads to a broad clinical spectrum, ranging from sub-clinical infection or an influenza-like disease known as dengue fever (DF) to a severe, sometimes fatal disease characterized by haemorrhage and shock, known as dengue haemorrhagic fever/dengue shock syndrome (DHF/ DSS). DENVs are transmitted to humans mainly by the bites of Aedes aegypti and Aedes albopictus mosquitoes. Dengue is the most important arthropodborne virus in tropical and subtropical countries, with an estimated 50 million infections each year, resulting in 500,000 cases of DHF/DSS and 25,000 deaths.
Like other flaviviruses, dengue virus has a singlestranded, Positive -sense RNA genome of ~10,700 nucleotides, surrounded by a nucleocapsid and covered by a lipid envelope that contains the viral glycoproteins. The RNA genome contains a single open reading frame (ORF) flanked by two untranslated regions (5' and 3'UTRs). The single ORF encodes a precursor polyprotein, which is co-and posttranslationally cleavaged resulting in the formation of three structural proteins, Capsid (C), membrane (M), and envelope (E), and seven non-structural proteins, NS1, NS2a, NS2b, NS3, NS4a, NS4b, and NS5. There is no specific antiviral therapy or vaccine in clinical use for dengue fever. Medical care is supportive in nature and focuses on monitoring and administration of fluids to prevent dehydration and shock, medications to lower fever and reduce pain, and management of bleeding complications.
Global scenario of Dengue virus infection
DENV-1 was first isolated by Ren Kimura and Susumu Hotta in Japan in 1943 (Kimura and Hotta, 1943 ). An epidemic of DF involving at least 2,00,000 cases had International Journal of Applied Sciences and Biotechnology ISSN: 2091 ISSN: -2609 occurred between 1942 and 1944 during World War II in Japanese port cities such as Nagasaki, Kobe, and Osaka. The infections originated from persons returning from the tropics, in particular Southeast Asia and the Pacific islands (Hotta et al, 2000) . A few months after the first isolation of DENV-1 in Japan, Albert Bruce Sabin and Walter Schlesinger isolated DENV-1 from Hawaiian and shortly thereafter, DENV-2 from Papua New Guinean samples (Sabin and Schlesinger, 1945) . They demonstrated that these viruses were antigenically related, yet distinct, and they could be distinguished by the hemagglutination inhibition (HI) assay. In the late 1960s, DHF fatality has been reported to be as high as 41.3% (Sumarmo et al., 1987) when healthcare providers understandably were still unfamiliar with the disease. Today, DHF fatality rates can exceed 20% without proper treatment, but can be brought down to 1% with proper medical care (WHO, 1999) . Although there were various speculations about the earliest description of denguelike diseases in historical accounts (Halstead, 1980 (Halstead, et al, 1980 ) the disease now known as DHF was first recognised in Manila, the Philippines in 1953 (Quinlos et al., 1954) . Viruses similar to DENV-1 and DENV-2 were isolated from Manila patients in 1956 by William Hammond and were called DENV-3 and DENV-4. Dengue viruses of multiple serotypes were subsequently isolated from patients of another DHF epidemic in Bangkok, Thailand in 1958 (Hammond et al 1960 . It is now known all four serotypes of dengue virus can cause DHF. DHF/DSS outbreaks were mainly restricted to Southeast Asia until the early 1980s (Halstead, 1980) . Since then, dengue transmission has intensified and DHF/DSS outbreaks are now frequent in most tropical countries. To this day, DHF/DSS remains a leading cause of hospitalisation and death among children in Southeast Asia. Outside the region, the disease burden of dengue is most acutely felt in Central and South America where 24 countries have reported laboratory-confirmed DHF between 1981 and 1997 (Monath et al 1994) .
DENV-1 can be divided into five genotypes based on the complete E gene sequence as described by Goncalvez et al. (2002) . Earlier work by Rico-Hesse (1990) also classified DENV-1 into five groups based on the 240-nucleotide E/NS1 junction sequence. The DENV-1 genotypes all have a wide area of distribution apart from genotype III (sylvatic) and genotype II which consists of Thai strains from the 1950s and 1960s. Viruses of genotype I and IV have recently been implicated as causing epidemics in the Pacific between 2000 and 2004 and genotype V viruses are frequently isolated during epidemics in the Americas. However, it is still inconclusive whether any of these three DENV-1 genotypes can be consistently associated with causing more severe dengue. DENV-2 is the most studied serotype among the dengue viruses. Twiddy et al. (2002) proposed the existence of six genotypes of DENV-2 (Table 2) based on the complete E gene sequence following earlier work by Rico-Hesse (1990) and Lewis et al. (1993) . Sylvatic DENV-2 strains that are closely related have been isolated from several countries in West Africa and Malaysia, two locations that are far apart, leading to hypothesise that the DENV sylvatic ancestor arose in the Asian-Oceanic region before diverging into today's four DENV serotypes. The first DHF epidemic in the Americas occurred after an introduction of the Asian II genotype to Cuba in 1981 (Guzman et al., 1995) . Likewise, the America/Asian genotype (genotype III) has been reported to have replaced the pre-existing American genotype (genotype V) in the Western Hemisphere and is considered to be the DENV-2 genotype with the highest epidemiological impact.
The current genotype classification for DENV-3 follows the nomenclature proposed by Lanciotti et al. (1994) which recognised four DENV-3 genotypes based on prM/E sequences (Table 3 ). These four genotypes are similar to the four groups using a 195-nucleotide region at the 5' terminus of the E gene.
Introduced to the Americas via Nicaragua in 1994, genotype III DENV-3 is now widely found in Central and Southern America (Balmaseda et al., 1999; Usuku et al., 2001; Messer et al., 2003) and is considered as the most virulent of the four DENV-3 genotypes. It is worthy of note that genotype IV has never been associated with any DHF epidemics. Although their existence is anticipated through the presence of DENV-3 antibodies in non-human canopy-dwelling primates, no sylvatic lineage of DENV-3 has been found thus far (Rudnick, 1984) . Table 2 : DENV-2 genotypes according to Twiddy et al. (2002) . (Klungthong et al., 2004) . Genotype II DENV-4 is the most widespread of the four following an introduction to the Western hemisphere in 1981, possibly via the Pacific islands (Lanciotti et al., 1997; Foster et al., 2003) . Although DENV-4 is the least frequently sampled serotype, it is often associated with haemorrhagic fever during secondary infection (Vaughn et al., 2000) . 
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Scenario of Dengue virus infection in South East Asia Region
Of the total world population of 6.2 billion, countries of the South-East Asia Region (SEAR) account for 1.5 billion (24%). On that scale, of the 2.5 billion people (living in the tropics and sub-tropics) at risk of DF/DHF, 52%, i.e. 
Nepalese scenario of Dengue virus infection
DF is an emerging disease affecting Nepal since 2004 (Pandey et al., 2004) There was an concern of the disease in Nepal after the Indian and Pakistani epidemic of DF/DHF, which claimed more than 100 deaths and more increasingly several thousand cases in the year (Gupta et al., 2006 There was an outbreak which was observed in 9 districts of Tarai region in Nepal in 2006 (Pandey et al., 2008 
Outcome of Dengue Virus Infection
A person could suffer from dengue infection four times throughout his/her lifetime, once for each of the four DENV serotypes. Both primary (first) and secondary (subsequent) infections with any serotype of DENV can result in either the clinically less severe DF or the more severe DHF (Rosen et al, 1977) . A primary dengue infection confers the recovered patient life-long immunity against the infecting serotype and a brief protection against infection by other DENV serotypes (Sabin et al, 1952) . However, epidemiological data and some studies suggest that the immunity thus gained, after the lapse of the temporary cross-serotypic protection, increases the probability of an individual developing DHF when infected by a second heterologous DENV serotype Halstead et al., 1967; Halstead et al., 1970) . A hypothesis to explain this phenomenon, called antibody-dependent enhancement (ADE), proposes that pre-existing sub-neutralizing antibodies from the primary infection and the second infecting DENV serotype form complexes that bind to cells bearing Fcγ receptor (FcγR) (monocytes and B cells) leading to increased virus uptake and replication. (Halstead et al, 1988) .
